Connections between body composition and dysregulation of islet α- and β-cells in type 2 diabetes

Miao, Jia-xi; Xu, Jia-ping; Wang, Rui; Xu, Yu-xian; Xu, Feng; Wang, Chun-hua; Yu, Chao; Zhang, Dong-mei; Su, Jian-bin

doi:10.1186/s13098-023-01250-3

Diabetology & Metabolic Syndrome

Table 3 Impacts of body composition on outcomes of islet α- and β-cell functions according to multivariate linear regression analysis in all patients with T2D

From: Connections between body composition and dysregulation of islet α- and β-cells in type 2 diabetes

Models	B (95% CI)	β	t	p	Partial R²
Impacts of trunk fat mass on lnISI_C-peptide
Model 0: crude	− 0.061 (− 0.074 to − 0.0148)	− 0.330	− 9.416	< 0.001
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP and statin medication	− 0.050 (− 0.073 to − 0.028)	− 0.274	− 4.449	< 0.001
Model 2: additionally adjusted for ALT, albumin, lipid profiles, UA, eGFR and TBI	− 0.036 (− 0.058 to − 0.014)	− 0.196	− 3.213	0.001
Model 3: additionally adjusted for HbA1c, fasting glucagon, AUC_glucagon and glucose-lowering therapies	− 0.037 (− 0.059 to − 0.016)	− 0.203	− 3.391	0.001
Model 4: additionally adjusted for trunk lean mass, limb fat mass and limb lean mass	− 0.045 (− 0.070 to − 0.021)	− 0.247	− 3.628	< 0.001	10.9%
Impacts of trunk fat mass on lnAUC_C-peptide
Model 0: crude	0.052 (0.040 to 0.063)	0.317	9.014	< 0.001
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP a nd statin medication	0.041 (0.021 to 0.060)	0.252	4.117	< 0.001
Model 2: additionally adjusted for ALT, albumin, lipid profiles, UA, eGFR and TBI	0.030 (0.011 to 0.050)	0.186	3.071	0.002
Model 3: additionally adjusted for HbA1c, fasting glucagon, AUC_glucagon and glucose-lowering therapies	0.032 (0.014 to 0.050)	0.198	3.508	< 0.001
Model 4: additionally adjusted for trunk lean mass, limb fat mass and limb lean mass	0.037 (0.017 to 0.058)	0.229	3.581	< 0.001	8.2%
Impacts of limb lean mass on fasting glucagon
Model 0: crude	− 2.099 (− 2.862 to − 1.336)	− 0.196	− 5.402	< 0.001
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP and statin medication	− 2.322 (− 3.826 to − 0.817)	− 0.217	− 3.029	0.003
Model 2: additionally adjusted for ALT, albumin, lipid profiles, UA, eGFR and TBI	− 2.787 (− 4.315 to − 1.259)	− 0.261	− 3.581	< 0.001
Model 3: additionally adjusted for HbA1c, ISI_C-peptide, AUC_C-peptide and glucose-lowering therapies	− 2.690 (− 4.244 to − 1.136)	− 0.251	− 3.399	0.001
Model 4: additionally adjusted for trunk fat mass, trunk lean mass and limb fat mass	− 2.420 (− 4.654 to − 0.187)	− 0.226	− 2.127	0.034	3.8%
Impacts of limb lean mass on AUC_glucagon
Model 0: crude	− 8.295 (− 11.06 to − 5.532)	− 0.214	− 5.894	< 0.001
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP and statin medication	− 9.083 (− 14.49 to − 3.676)	− 0.234	− 3.298	0.001
Model 2: additionally adjusted for ALT, albumin, lipid profiles, UA, eGFR and TBI	− 10.32 (− 15.85 to − 4.788)	− 0.266	− 3.664	< 0.001
Model 3: additionally adjusted for HbA1c, ISI_C-peptide, AUC_C-peptide and glucose-lowering therapies	− 8.920 (− 14.55 to − 3.293)	− 0.230	− 3.112	0.002
Model 4: additionally adjusted for trunk fat mass, trunk lean mass and limb fat mass	− 8.454 (− 16.55 to − 0.357)	− 0.218	− 2.050	0.041	2.3%

ISI_C-peptide C-peptide-substituted Matsuda’s index, lnISI_C-peptide natural log-transformed ISI_C-peptide, AUC_C-peptide C-peptide area under curve during OGTT, lnAUC_C-peptide natural log-transformed AUC_C-peptide, AUC_glucagon glucagon area under the curve during OGTT, BMI body mass index, ALT alanine aminotransferase, TBI total bilirubin, UA uric acid, HbA1c glycosylated haemoglobin A1c, eGFR estimated glomerular filtration rate

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com